Oramed Pharmaceuticals Inc. reported its financial results for the second quarter of 2025, revealing a revenue of $2 million, a significant increase from zero revenue in the same period last year. The company attributed this revenue to the recognition of deferred income related to its license agreement with Hefei Tianhui Biotech Co., Ltd. (HTIT). Despite this revenue, Oramed recorded a net income of $5.6 million for the six months ended June 30, 2025, down from $10.7 million in the prior year, primarily due to a decrease in financial income and increased research and development expenses.
The company’s total assets as of June 30, 2025, stood at approximately $161.7 million, a slight increase from $155.3 million at the end of 2024. However, cash and cash equivalents saw a notable decline, dropping to $15.8 million from $54.4 million, largely due to investments in various projects, including Alpha Tau Medical Ltd. and real estate ventures. Oramed's total liabilities decreased to $8.1 million from $9.9 million, reflecting a reduction in accounts payable and accrued expenses.
Strategically, Oramed has been active in expanding its operations and partnerships. The company is in the process of establishing a joint venture with HTIT, aimed at developing and commercializing oral insulin products. However, the initial closing of this joint venture has been delayed due to regulatory challenges stemming from U.S.-China trade tensions. As a result, Oramed has paused plans for a Phase 3 clinical trial in the U.S. while exploring alternative partnerships to advance its oral insulin program.
In terms of operational metrics, Oramed's employee headcount remained stable, and the company continues to focus on its research and development activities, which are expected to be its primary expenditure moving forward. The company has also engaged in stock repurchase activities, having repurchased 163,869 shares under its buyback program, which has been extended for another year.
Looking ahead, Oramed anticipates that its research and development expenses will increase as it prepares for the revised Phase 3 clinical trial. The company remains optimistic about its financial position, with a working capital surplus of approximately $95.3 million as of June 30, 2025, which it believes will support its planned activities for at least the next 12 months.
About ORAMED PHARMACEUTICALS INC.
Oramed Pharmaceuticals develops innovative oral drug delivery solutions, primarily focusing on oral insulin and proteins for diabetes and other conditions. Its core business involves research, clinical trials, and strategic partnerships to commercialize oral biologic therapies. The company owns extensive intellectual property, collaborates with global partners, and targets markets worldwide, aiming to improve patient convenience and treatment efficacy through proprietary technology and strategic licensing.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.